CSPC Signs Cooperation Agreement with AstraZeneca for Joint Confirmatory Research Targeting Lung Cancer

Shanghai JMT-Bio Inc., a subsidiary of CSPC, held a signing ceremony with AstraZeneca Investment (China) Co., Ltd. for a joint confirmatory research cooperation project targeting lung cancer at the 6th China International Import Expo on November 6, 2023. Xiang Anbo, President of the Clinical Business Unit of CSPC, and Yang Xiugao, Senior Medical Director, as well as Chen Bing, Vice President of AstraZeneca China and Head of International Business Expansion Cooperation and Strategic Investment, Chen Kangwei, General Manager of AstraZeneca China Oncology Business Unit, and Liu Ming, Vice President of AstraZeneca China and Head of Oncology Lung Cancer Business Unit, attended the signing ceremony.

In the past year, remarkable research results have been achieved in the treatment of non-small cell lung cancer with EGFR 20 exon insertion mutation (EGFR ex20ins) using humanized EGFR monoclonal antibody developed by CSPC in combination with osimertinib, AstraZeneca's blockbuster product in the lung cancer field. The related research data were published in Nature Communication, receiving widespread recognition from the international academic community. At the same time, a key phase II single-arm study for the indication of EGFR 20 exon insertion mutation in non-small cell lung cancer has also made good progress and has yielded promising clinical research data. The study-related drugs will be expeditiously applied for market approval. Based on the fruitful cooperation, Yang Xiugao and Liu Ming, as representatives of both parties, jointly signed the cooperation agreement, aiming to continue their collaboration in the phase III confirmatory study of this indication.

During the ceremony, Chen Kangwei stated that the strategic cooperation between AstraZeneca and CSPC is a powerful alliance to drive more innovative drugs to market. This is of great significance for addressing the unmet medical needs of patients.

Xiang Anbo expressed that the collaboration has generated outstanding research results. He hopes that the successful experience can be replicated across different product pipelines so as to jointly address medical challenges in fields such as lung cancer globally.

Furthermore, the two parties have signed a strategic cooperation framework agreement, agreeing to explore comprehensive cooperation in the field of tumor treatment gradually. Both parties hope that, under the joint efforts of their shared vision, the two leading pharmaceutical companies at home and abroad can have more intersections in more treatment areas and R&D pipelines, thus contributing to human health.